Frontiers in Pediatrics (Nov 2022)

Real-world Biapenem vs. Meropenem in the treatment of severe community-acquired pneumonia in children: A propensity score matching analysis

  • Xuemei Tao,
  • Xuemei Tao,
  • Changjing Xu,
  • Xiaoyan Zhong,
  • Yao Mou,
  • Jingwei Li,
  • Xuping Yang,
  • Yilan Huang,
  • Yilan Huang

DOI
https://doi.org/10.3389/fped.2022.1047595
Journal volume & issue
Vol. 10

Abstract

Read online

ObjectiveTo compare the real-world efficacy and safety of Biapenem and Meropenem for treating severe community-acquired pneumonia (SCAP) in children.MethodsWe retrospectively evaluated 915 children with SCAP who were treated with Biapenem or Meropenem from August 2018 to June 2022. A 1:1 propensity score matching (PSM) analysis was used to reduce the actual baseline difference between groups.Results416 patients participated in the analysis after PSM (Biapenem: Meropenem = 1:1). For the Biapenem group and Meropenem group, the effective rates were 90.4% and 90.9%, respectively (p = 1.0) and the incidence of adverse reactions were 7.7% and 7.2%, respectively (p = 1.0). There were no statistical differences between Biapenem and Meropenem.ConclusionIn general, the efficacy and safety of Biapenem are comparable to Meropenem in the treatment of children with SCAP.

Keywords